Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Entecavir Goes To Antiviral Advisory Committee March 11

This article was originally published in The Pink Sheet Daily

Executive Summary

The oral nucleoside analogue is pending at FDA for treatment of chronic hepatitis B infection and is receiving a priority review. Bristol's Phase III trials show statistically significant improvements compared to GlaxoSmithKline's Epivir-HBV.

You may also be interested in...



Entecavir Post-Marketing Surveillance Study To Track Cancer Risk

Entecavir preclinical carcinogenicity studies exhibit an increased risk of tumors in rodents. Bristol-Myers Squibb's proposed post-marketing study may not be long enough to track cancers with long latency, FDA says. Advisory committee will review entecavir for treatment of hepatitis B on March 11.

Entecavir Post-Marketing Surveillance Study To Track Cancer Risk

Entecavir preclinical carcinogenicity studies exhibit an increased risk of tumors in rodents. Bristol-Myers Squibb's proposed post-marketing study may not be long enough to track cancers with long latency, FDA says. Advisory committee will review entecavir for treatment of hepatitis B on March 11.

Roche Pegasys sBLA Filing For Hepatitis B Could Receive Priority Review

Roche announced simultaneous U.S. and European submissions July 21; six-month review would set user fee date at mid-January. Roche is likely to highlight superiority to GlaxoSmithKline’s Epivir-HBV and efficacy in HBeAg-negative patients in promotions.

Topics

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel